Associate George Zacharodimos highlights recent decisions that find an excessive price infringement in the pharmaceuticals sector and how these decisions introduce a cost-plus approach to identify excessive pharmaceutical prices.
An extract from GCR’s The Guide to Life Sciences - First Edition. The whole publication is available at https://globalcompetitionreview.com/guide/guide-life-sciences/first-edition.